Ustekinumab Biosimilar is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 3 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Ustekinumab Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ustekinumab Biosimilar is expected to reach an annual total of $443 mn by 2039 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ustekinumab Biosimilar Overview
Ustekinumab biosimilar (ABP-654) is under development for the treatment of plaque psoriasis. It is administered by the subcutaneous route in the form of solution. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$26,323 million for the fiscal year ended December 2022 (FY2022), an increase of 1.3% over FY2021. In FY2022, the company’s operating margin was 36.6%, compared to an operating margin of 29.4% in FY2021. In FY2022, the company recorded a net margin of 24.9%, compared to a net margin of 22.7% in FY2021. The company reported revenues of US$6,986 million for the second quarter ended June 2023, an increase of 14.4% over the previous quarter.
For a complete picture of Ustekinumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.